Evidence map›Paper›PMID 39720368›Full record

ArticleCureus2024

Hepatocellular Carcinoma Developing in a Patient 29 Years After Achieving Sustained Virologic Response for Hepatitis C With Interferon Therapy: A Case Report.

Yosuke Maezawa, Yukiko Kodama, Hiroyuki Ariga, Junya Kashimura, Toshiyuki Irie

Abstract readCase Reports
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yosuke MaezawaDepartment of Internal Medicine, Mito Kyodo General Hospital, Mito, JPN.
Yukiko KodamaDepartment of Internal Medicine, Mito Kyodo General Hospital, Mito, JPN.
Hiroyuki ArigaDepartment of Gastroenterology, Mito Kyodo General Hospital, Mito, JPN.
Junya KashimuraDepartment of Gastroenterology, Mito Kyodo General Hospital, Mito, JPN.
Toshiyuki IrieDepartment of Radiology, Mito Kyodo General Hospital, Mito, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a case of an 87-year-old female with a ruptured hepatocellular carcinoma (HCC). She presented with sudden epigastric and right upper abdominal pain. The physical examination revealed mild tenderness in the right upper abdomen, a positive Murphy's sign, and no jaundice. Laboratory tests showed mild anemia and elevated PIVKA-II (prothrombin induced by vitamin K absence II) levels. Abdominal ultrasound and CT revealed a large hypervascular mass in the liver, along with ascites and portal vein thrombosis. The patient had received interferon therapy for hepatitis C virus (HCV) 29 years before her presentation and blood tests and imaging examinations had confirmed sustained undetectability for HCV ribonucleic acid (RNA) and the absence of HCC for five years following treatment. HCV RNA remained undetectable at the time of her admission, and it was presumed that it had been negative for 29 years post-treatment, with no evidence of re-exposure. The patient had not attended any follow-up appointments. While there have been no reported cases of a patient developing HCC 29 years after achieving sustained virologic response (SVR), our case suggests that the absence of HCC risk is not guaranteed, even after a prolonged period post-SVR. Therefore, periodic imaging tests such as abdominal ultrasound or CT may be beneficial in detecting potential HCC, even long after achieving SVR.

Indexed as

direct-acting antiviral drugshepatitis c virus (hcv)hepatocellular carcinoma (hcc)interferon therapysustained virologic response (svr)

Identifiers

PMID39720368
PMCPMC11667130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.